What Are Biostimulator Injections and How Do They Work?

Biostimulator injections are a class of injectable treatments that prompt your own body to rebuild collagen and other structural proteins, rather than simply filling in wrinkles or hollows with an inert gel. The core idea is straightforward: a biocompatible material is injected beneath the skin, triggers a controlled immune and cellular response, and over the following weeks to months your tissue produces new collagen around and in place of the dissolving material. The result is gradual, often appearing over several treatment sessions, and tends to last longer than traditional fillers because the improvement comes from your own tissue rather than an implanted substance.

How the Process Actually Works

Every biostimulator relies on a version of the same biological chain reaction, though the details differ by material. When tiny particles of a foreign but biocompatible substance are placed in the deep skin or just above the bone, your immune system recognizes them as something that doesn’t belong. Immune cells called macrophages arrive and begin surrounding the particles. This kicks off a low-grade inflammatory process that, crucially, stays controlled and doesn’t cause obvious swelling or redness at the surface. The macrophages send chemical signals that recruit fibroblasts, the cells responsible for producing collagen and other connective-tissue components.

Over time, fibroblasts lay down new collagen fibers around the biostimulator particles. As the injected material slowly breaks down and is absorbed, the new collagen remains behind as a kind of internal scaffolding. With poly-L-lactic acid, for instance, the particles gradually break down into lactic acid monomers while newly made collagen replaces the lost volume, providing structural support to the skin.¹ The net effect is skin that looks fuller and firmer not because something is sitting under the surface holding it up, but because the tissue itself has been rebuilt.

The Major Types of Biostimulators

Several materials are used as biostimulators, and each has a somewhat different profile in terms of how quickly results appear, how long they last, and what kind of tissue remodeling they produce.

Poly-L-Lactic Acid (PLLA)

PLLA, best known by its brand name Sculptra, consists of tiny irregular flakes ranging from about 2 to 200 micrometers in size. These particles trigger macrophage activity and a foreign body response at the surface of each flake, which stimulates the surrounding tissue to lay down new collagen. Because the particles need to degrade gradually through hydrolysis, the collagen-building process unfolds slowly, and most people need two to three treatment sessions spaced several weeks apart before the full effect is visible.¹ A systematic review found that PLLA maintained its effects for up to 25 months.²

Calcium Hydroxylapatite (CaHA)

CaHA, sold as Radiesse, takes a slightly different approach. Its microspheres are suspended in a carboxymethylcellulose gel that provides some immediate volume the moment it’s injected. Then, as the gel carrier is absorbed, the CaHA microspheres act as a scaffold, meaning cells can grow along and around them, stimulating new collagen production and broader extracellular matrix renewal.³ Unlike PLLA, CaHA’s ceramic surface activates a somewhat different arm of the immune response, promoting what researchers describe as regenerative macrophage behavior rather than the classic foreign body reaction seen with polymer particles.¹ Results from CaHA typically last around 12 to 18 months.²

Polycaprolactone (PCL)

PCL, marketed as Ellansé, combines immediate volumizing from a gel carrier with long-term collagen stimulation and new blood vessel formation.⁴ PCL microspheres persist in tissue for a notably long time. Biopsy studies have shown that at nine months after injection, both early-stage (type III) and mature (type I) collagen are present around the microspheres, and by 21 months the collagen has matured to predominantly type I, the stronger, more organized form that gives skin its tensile strength.⁵ This long persistence is part of why PCL-based products are available in formulations designed to last from one to four years, depending on the version chosen.

Polynucleotides and Polydeoxyribonucleotides

A newer category involves polynucleotides (PN) and polydeoxyribonucleotides (PDRN), which are derived from salmon or trout DNA fragments. These work by a different pathway than the particle-based stimulators above. PDRN, composed of shorter DNA sequences, improves skin condition partly by activating adenosine receptors and supporting the cell’s own processes for building new DNA and RNA building blocks.⁶ Rather than provoking a foreign body response, these products work more at a cellular-signaling level, promoting tissue repair and hydration. They’re increasingly popular in parts of Asia and Europe for overall skin quality improvement rather than volume restoration.

Biostimulatory Hyaluronic Acid

You may already know hyaluronic acid as the basis for traditional dermal fillers, but some newer HA formulations are designed specifically to stimulate tissue remodeling rather than just fill space. These hybrid complexes contain a mix of low and high molecular weight HA that promotes restructuring across multiple layers of the skin, improving elasticity, firmness, and hydration while reducing wrinkle depth.⁷ These products sit in a gray zone between classic fillers and true biostimulators, and their categorization is still debated among clinicians.

More Than Just Collagen

The popular understanding of biostimulators is that they “build collagen,” and while that’s accurate, it undersells what actually happens in the tissue. Research on CaHA has shown that beyond collagen, these treatments also stimulate elastin production, which gives skin its snap-back quality. Studies examining tissue at four and nine months after CaHA implantation found progressive increases in cell-proliferation markers as well as increased density of markers for new blood vessel growth. That blood vessel formation matters because better blood flow means improved nutrient delivery to the skin, which supports ongoing tissue maintenance well beyond the initial treatment period.⁸

Over time, the treated area develops a denser, more uniform arrangement of fibers in both the superficial and deep layers of the skin. This is why patients often report that their skin doesn’t just look fuller but actually feels different: firmer, more elastic, with a quality that’s hard to achieve with surface-level skincare alone.⁸

How Biostimulators Differ from Traditional Fillers

The practical distinction matters if you’re deciding between a biostimulator and a conventional hyaluronic acid filler. A standard HA filler works the way a pillow works: it occupies space. Inject it into a nasolabial fold and the fold looks softer immediately because there’s now a cushion of gel sitting under it. The gel doesn’t make your body do anything; it just sits there until enzymes gradually break it down over six to eighteen months.

A biostimulator, by contrast, asks your body to do the heavy lifting. The injected material is a trigger, not a permanent implant. This means results appear more gradually, often requiring patience and multiple sessions. But it also means the outcome tends to look more natural over time, since the volume comes from your own tissue rather than an injected substance that can sometimes shift or feel unnaturally firm. CaHA is a bit of a hybrid in that its gel carrier provides some immediate volume correction on top of the longer-term biostimulatory effect.⁹

This fundamental difference creates a trade-off. HA fillers give you a predictable, immediate result and can be dissolved with an enzyme called hyaluronidase if something goes wrong. Biostimulators offer a more gradual and arguably more natural-looking improvement, but they’re much harder to reverse if you’re unhappy with the outcome.

Injection Technique and Why It Matters

Biostimulators are more technique-sensitive than many fillers. The depth of injection, the dilution of the product, and even whether a needle or a blunt-tipped cannula is used can meaningfully affect results and safety. Cadaver studies comparing needle versus cannula for deep injections found that cannulas kept the product confined to the intended deep layer, whereas needles caused the material to end up at multiple depths in about 60% of injections.¹⁰ This precision matters because placing biostimulator particles too superficially in the skin is one of the leading causes of visible nodules.

CaHA, in particular, is often diluted or “hyperdiluted” with saline or lidocaine for skin-tightening applications where the goal is broad, even distribution rather than focal volume. The dilution ratio changes the product’s physical behavior dramatically, affecting how it flows through tissue and how evenly the microspheres distribute themselves. Getting this wrong can lead to clumping, uneven results, or complications. This is part of why practitioners who specialize in biostimulators tend to emphasize training and technique even more than product selection.

Risks and the Nodule Problem

The most distinctive risk with biostimulators is nodule formation. Because these products work by provoking a tissue response, that response can occasionally go too far or happen in the wrong location. Nodules can be broadly divided into two categories: noninflammatory lumps caused by product clumping, and inflammatory granulomas where the immune system mounts an exaggerated reaction to the material.

Noninflammatory nodules are often a technique issue. Injecting too superficially, using too high a concentration of microspheres, skipping post-injection massage, injecting too much product, not waiting long enough between sessions, or improperly preparing the product can all cause particles to cluster together and form a palpable lump.¹¹ With PLLA in particular, proper reconstitution time is critical: the powder needs to hydrate fully before injection, and rushing this step has historically been a major source of complications.

Inflammatory granulomas are rarer and less predictable. They represent an excessive immune response and can appear weeks, months, or occasionally even years after treatment. The immune system essentially walls off the foreign material with a dense capsule of inflammatory cells, creating a firm, sometimes tender lump. These are more difficult to treat and represent one of the genuine downsides of biostimulators compared to HA fillers.

What Happens When Something Goes Wrong

If you get an HA filler and develop a lump or vascular compromise, hyaluronidase can dissolve the product rapidly. No such easy reversal exists for biostimulators. There is no definitive treatment for complications arising from collagen biostimulator injections, and a variety of approaches have been tried, including saline infusion, diluted corticosteroid injections, 5-fluorouracil, hyaluronidase, and sodium thiosulfate for CaHA-specific issues.¹²

For CaHA nodules specifically, researchers have explored focused mechanical vibration as a noninvasive treatment option. The idea is that vibration can help break up and redistribute clumped particles. In more persistent cases where a fibrous capsule has formed around the nodule, collagenase injections can help enzymatically degrade the collagen holding the particles together. Hyaluronidase, though designed for HA, might assist in dispersing CaHA particles by breaking down the natural hyaluronic acid in the surrounding tissue. Neither collagenase nor hyaluronidase, however, actually dissolves the CaHA particles themselves.¹³

This irreversibility is arguably the single most important thing to understand before choosing a biostimulator. The gradual, natural-looking results are appealing, but you need to be confident in both the product choice and the practitioner’s skill, because undoing the outcome is far harder than with HA-based options.

Beyond the Face

Biostimulators are increasingly being used off-label on body areas, building on their track record in the face. The logic is the same: inject a biostimulatory material into skin that has lost its structural integrity, and let the resulting collagen production tighten and improve skin quality. Body areas being treated include the neck, décolletage, upper arms, abdomen, thighs, and buttocks.¹⁴

For body applications, CaHA is typically used in a hyperdiluted form so it spreads across a larger surface area, focusing on skin tightening rather than volume restoration. PLLA has also been studied for body use, including treatment of skin laxity, cellulite, and stretch marks, with reports of good patient satisfaction and mostly minor side effects.¹⁵ The evidence base for body applications is thinner than for facial use, and much of it comes from case series and small studies rather than large randomized trials. Consensus guidelines exist for some indications, but these are still relatively new territory.

The Collagen Timeline

One of the most common sources of frustration with biostimulators is the timeline. Unlike fillers that transform your appearance in the time it takes to walk out of the clinic, biostimulators work on your body’s schedule. For PLLA, the visible improvement typically begins around four to six weeks after the first session and continues to build over the following months. Most treatment plans involve two or three sessions spaced several weeks apart, with the full effect emerging only after the final session has had time to work.

The collagen that forms goes through its own maturation. Early on, the tissue produces mainly type III collagen, which is softer, less organized, and often associated with wound healing. Over subsequent months, this is gradually replaced or supplemented by type I collagen, the dominant and mechanically stronger form found in healthy adult skin. Biopsy studies of PCL-treated tissue confirm this progression clearly, with type III collagen prominent at nine months and type I becoming dominant by 21 months.⁵ A study comparing PLLA and polydioxanone (PDO) threads as biostimulators found that both favored type III collagen production relative to subcision alone, suggesting that the type III-to-type I progression is a general feature of biostimulation rather than something unique to one product.¹⁶

This slow maturation is actually a feature, not a bug. The gradual change means people around you are less likely to notice a sudden shift in your appearance, and the evolving tissue quality can continue to improve long after the injections themselves are done.

How Product Consistency Affects Outcomes

Each biostimulator has distinct physical properties that determine how it behaves once injected. Researchers describe these properties using measures of stiffness, elasticity, and flow behavior. In practical terms, these properties determine whether a product will stay where it’s placed, how easily it can be molded after injection, and whether it resists the mechanical forces of facial movement.

CaHA at standard concentration, for example, is considerably stiffer than PLLA, which gives it that immediate volumizing capacity but also means it can form visible lumps if placed too superficially. When CaHA is diluted for skin-tightening applications, its stiffness drops dramatically, making it flow more easily through a cannula and spread more evenly through tissue. PLLA has lower inherent stiffness and is typically reconstituted into a relatively thin suspension, which makes it well-suited for broad distribution across the face but less useful when focal, structural volume is needed.¹⁷ Understanding these differences helps explain why a practitioner might choose CaHA for cheekbone definition but PLLA for overall skin quality improvement across the temples and midface.

A Global Market with Uneven Evidence

The biostimulator landscape varies significantly depending on where you are. In the United States, the FDA has cleared PLLA and CaHA for specific facial indications. In Europe, a broader range of products including PCL-based fillers and polynucleotide treatments are available. In parts of Asia, polynucleotides and PDRN are among the most popular injectable categories, while CaHA and PLLA may have different regulatory statuses than in Western markets.

A cross-sectional study of medical professionals and patients in China found that biostimulators were predominantly used for natural aesthetic outcomes, but that local clinical and basic research data remained insufficient relative to global standards.¹⁸ This gap between enthusiastic clinical adoption and formal evidence is a theme across many markets. Practitioners often share techniques and outcomes at conferences and through social media, moving faster than the peer-reviewed literature can keep up with. That creates real innovation but also real risk for patients who may receive treatments based more on practitioner experience than on robust clinical trial data.

If you’re considering a biostimulator, it’s worth asking your practitioner not just which product they recommend but why, what evidence supports using it for your particular concern, and how many times they’ve performed the specific procedure. In a field where technique matters as much as product selection, experience counts for a lot.

1
PubMed Central. The Immunologic Spectrum of Biostimulators and Its Clinical Importance
2
SpringerLink / Aesthetic Plastic Surgery. Efficacy, Durability, and Safety of Collagen Biostimulators Based on Poly-L-Lactic Acid (PLLA) and Calcium Hydroxyapatite (CaHA) in the Face: A Systematic Review
3
PubMed Central. The Role of Calcium Hydroxylapatite (Radiesse) as a Regenerative Aesthetic Treatment: A Narrative Review
4
Medicine in Evolution. What Are Biostimulator Injections and How Do They Work?
5
PubMed Central. Objective Assessment of the Long-Term Volumizing Action of a Polycaprolactone-Based Filler
6
PubMed Central. Comparison of Polynucleotide and Polydeoxyribonucleotide in Dermatology: Molecular Mechanisms and Clinical Perspectives
7
Cureus. Use of Hyaluronic Acid Hybrid Complex to Treat Wrinkles in the Upper Third of the Face: A Case Report
8
Surgical & Cosmetic Dermatology. Biostimulators and their mechanisms of action
9
Thieme / Facial Plastic Surgery. Biostimulatory Injectables for Collagen Stimulation
10
PubMed Central. Consensus Recommendations for the Use of Hyperdiluted Calcium Hydroxylapatite (Radiesse) as a Face and Body Biostimulatory Agent
11
PubMed Central. Foreign Body Granulomas Reaction Related to Collagen Stimulatory Cosmetic Fillers: A Systematic Review
12
Journal of Cosmetic Dermatology. Complications of collagen biostimulators in Brazil: Description of products, treatments, and evolution of 55 cases
13
PubMed Central. Successful Treatment of Noninflammatory CaHA Nodules Using Focused Mechanical Vibration
14
Dermatologic Surgery. Global Consensus Guidelines for the Injection of Diluted and Hyperdiluted Calcium Hydroxylapatite for Skin Tightening
15
PubMed Central. Collagen Stimulators in Body Applications: A Review Focused on Poly-L-Lactic Acid (PLLA)
16
PubMed Central. Effect of poly-L-lactic acid and polydioxanone biostimulators on type I and III collagen biosynthesis
17
PubMed Central. Comparative Rheology of Hyaluronic Acid Fillers, Poly-l-lactic Acid, and Varying Dilutions of Calcium Hydroxylapatite
18
SpringerLink. Current Status and Perception of Biostimulators in China: A Cross-Sectional Study on Medical Professionals and Patients